Insmed to Present at September Investor Conferences, Announces Management Participation
ByAinvest
Thursday, Aug 21, 2025 7:03 am ET1min read
INSM--
The company has a robust pipeline of respiratory therapies, including brensocatib, a small molecule oral inhibitor of dipeptidyl peptidase 1 (DPP1), which has shown consistent efficacy and safety across multiple subgroups in the ASPEN study [1]. The study demonstrated that brensocatib reduced pulmonary exacerbations, prolonged time to first exacerbation, and reduced lung function decline compared to placebo, with a similar safety profile across various patient types.
Additionally, Insmed presented data on treprostinil palmitil inhalation powder (TPIP) and ARIKAYCE® (amikacin liposome inhalation suspension) at the American Thoracic Society (ATS) 2025 International Conference. TPIP is being evaluated for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), while ARIKAYCE is a novel, inhaled formulation of amikacin used for refractory Mycobacterium avium complex (MAC) lung disease.
The company's commitment to advancing research and improving patient outcomes was evident in its presentations at the ATS conference. The breadth and depth of Insmed's scientific contributions reflect its dedication to transforming care for patients with serious diseases.
References:
[1] https://investor.insmed.com/2025-05-21-Brensocatib-Shows-Consistent-Efficacy-and-Safety-Across-Three-Prespecified-Subgroups-in-New-Data-from-Landmark-ASPEN-Study
Insmed Incorporated announced that management will present at the Wells Fargo 2025 Healthcare Conference and Morgan Stanley 23rd Annual Global Healthcare Conference in September. The presentations will be webcast live and available on the company's website. Insmed is a people-first global biopharmaceutical company developing therapies for serious diseases.
Insmed Incorporated, a global biopharmaceutical company, has announced that its management team will present at the Wells Fargo 2025 Healthcare Conference and the Morgan Stanley 23rd Annual Global Healthcare Conference in September. The presentations will be webcast live and available on the company's website. Insmed focuses on developing therapies for serious diseases, with a particular emphasis on respiratory conditions.The company has a robust pipeline of respiratory therapies, including brensocatib, a small molecule oral inhibitor of dipeptidyl peptidase 1 (DPP1), which has shown consistent efficacy and safety across multiple subgroups in the ASPEN study [1]. The study demonstrated that brensocatib reduced pulmonary exacerbations, prolonged time to first exacerbation, and reduced lung function decline compared to placebo, with a similar safety profile across various patient types.
Additionally, Insmed presented data on treprostinil palmitil inhalation powder (TPIP) and ARIKAYCE® (amikacin liposome inhalation suspension) at the American Thoracic Society (ATS) 2025 International Conference. TPIP is being evaluated for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), while ARIKAYCE is a novel, inhaled formulation of amikacin used for refractory Mycobacterium avium complex (MAC) lung disease.
The company's commitment to advancing research and improving patient outcomes was evident in its presentations at the ATS conference. The breadth and depth of Insmed's scientific contributions reflect its dedication to transforming care for patients with serious diseases.
References:
[1] https://investor.insmed.com/2025-05-21-Brensocatib-Shows-Consistent-Efficacy-and-Safety-Across-Three-Prespecified-Subgroups-in-New-Data-from-Landmark-ASPEN-Study
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comments
No comments yet